Citius Pharmaceuticals, Inc. — Director's Dealing 2016

Apr 15, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2016-03-30-06:00

Reporting Person: Webb Carol (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Common Stock	$0.001		Common Stock (0)		Direct

Footnotes

F1: On March 17, 2014 the Reporting Person was granted a ten-year option to purchase 100,000 shares of LMB common stock at an exercise price of $0.001 per share. The option vests in 1/3 increments over a three year period commencing on the first anniversary of the date of the grant, or March 17, 2015. On March 30, 2015 the Issuer entered into that certain Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB"). Pursuant to the Merger Agreement, the option was converted into an option to purchase 181,056 shares of the Issuer's common stock at a per share exercise price of $0.001. The option vests in 1/3 increments over a three year period with the first installment vesting on March 17, 2015.